× Key messages Background Findings Perspectives Expert commentary
Go back | list
format_size dark_mode
icon-previous icon-next

3-year follow-up on the 2017 CHAMP study

Key messages

  • Clinical improvements reported from the CHAMP study were maintained at three-year follow up.
  • There were no differences in headache frequency and disability between individuals taking amitriptyline or topiramate.
  • Migraine preventative medication can be stopped in youths with continued good functioning.